• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    Cencora Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation, Other Events, Financial Statements and Exhibits

    5/22/25 4:01:26 PM ET
    $COR
    Other Pharmaceuticals
    Health Care
    Get the next $COR alert in real time by email
    false 0001140859 0001140859 2025-05-22 2025-05-22 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

     

     

     

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION

    WASHINGTON, D.C. 20549

     

    FORM 8-K

     

    CURRENT REPORT

     

    Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

     

    Date of Report (Date of Earliest Event Reported): May 22, 2025

     

    Cencora, Inc.

    (Exact name of registrant as specified in its charter)

     

    Delaware   1-16671   23-3079390
    (State or other jurisdiction   (Commission   (I.R.S. Employer
    of incorporation)   File Number)   Identification No.)
             

    1 West First Avenue
    Conshohocken, PA

         

     

    19428-1800

    (Address of principal executive offices)       (Zip Code)

     

    Registrant’s telephone number, including area code:   (610) 727-7000

     

    Not Applicable

    Former name or former address, if changed since last report

     

    Securities registered pursuant to Section 12(b) of the Act:

     

    Title of each class Trading Symbol(s) Name of exchange on which registered
    Common stock COR New York Stock Exchange (NYSE)

     

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

     

    ¨  Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

    ¨  Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

    ¨  Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

    ¨  Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

     

    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

     

    Emerging growth company     ¨

     

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.     ¨

     

     

     

     

     

     

    Item 1.01 Entry into a Material Definitive Agreement.

     

    On May 22, 2025, Cencora, Inc. (the “Company”) completed the sale of €500,000,000 aggregate principal amount of the Company’s 2.875% Senior Notes due May 22, 2028 (the “2028 Notes”) and €500,000,000 aggregate principal amount of the Company’s 3.625% Senior Notes due May 22, 2032 (the “2032 Notes” and, together with the 2028 Notes, the “Notes”). The 2028 Notes were issued under and are governed by an Indenture, dated as of November 19, 2009 (the “Base Indenture”), between the Company and U.S. Bank Trust Company, National Association (as successor in interest to U.S. Bank National Association), as trustee (the “Trustee”), as supplemented and amended by a Sixteenth Supplemental Indenture, dated as of May 22, 2025, by and between the Company, U.S. Bank Europe DAC, UK Branch (the “Paying Agent”) and the Trustee (the “Sixteenth Supplemental Indenture” and, together with the Base Indenture, the “2028 Note Indenture”). The 2032 Notes were issued under and are governed by the Base Indenture, as supplemented and amended by a Seventeenth Supplemental Indenture, dated as of May 22, 2025, by and between the Company, the Paying Agent and the Trustee (the “Seventeenth Supplemental Indenture” and, together with the Base Indenture, the “2032 Note Indenture”). The 2028 Note Indenture and the 2032 Note Indenture are collectively referred to herein as the “Indentures.”

     

    The 2028 Notes bear interest at a rate of 2.875% per year, payable annually in arrears on May 22 beginning on May 22, 2026. The 2028 Notes will mature on May 22, 2028, unless earlier redeemed or repurchased. The Company may redeem the 2028 Notes, in whole or in part, at any time prior to April 22, 2028 at a “make-whole” redemption price set forth in the Sixteenth Supplemental Indenture (which redemption price may not be less than the principal amount of the 2028 Notes to be redeemed) and at any time on or after April 22, 2028 at 100% of the principal amount, in each case, plus accrued and unpaid interest, if any, to the date of redemption. The 2032 Notes bear interest at a rate of 3.625% per year, payable annually in arrears on May 22 of each year, beginning on May 22, 2026. The 2032 Notes will mature on May 22, 2032, unless earlier redeemed or repurchased. The Company may redeem the 2032 Notes, in whole or in part, at any time prior to February 22, 2032 at a “make-whole” redemption price set forth in the Seventeenth Supplemental Indenture (which redemption price may not be less than the principal amount of the 2032 Notes to be redeemed) and at any time on or after February 22, 2032 at 100% of the principal amount, in each case, plus accrued and unpaid interest, if any, to the date of redemption.

     

    The Notes are unsecured and unsubordinated obligations of the Company. The Notes rank equal in right of payment with all of the Company’s existing and future unsecured and unsubordinated indebtedness and the Notes are structurally subordinated to all indebtedness and other liabilities, including trade payables, of the Company’s subsidiaries.

     

    Subject to a number of important qualifications and exceptions, the Indentures, among other things, limit the Company’s ability and the ability of the Company’s restricted subsidiaries to create liens and to enter into sale and leaseback transactions and limit the Company’s ability to merge or consolidate with or into other entities or to sell, lease or convey all or substantially all of the Company’s and its restricted subsidiaries’ assets, taken as a whole.

     

    The Indentures provide for certain events of default which include (subject in certain cases to grace and cure periods), among others, nonpayment of principal or interest; breach of covenants or warranties in the Indentures; defaults under or failure to pay certain other indebtedness; failure to pay certain final judgments; and certain events of bankruptcy, insolvency, reorganization, administration or similar proceedings. Generally, if an event of default occurs, (i) the Trustee and the holders of at least 25% in aggregate principal amount of the then outstanding 2028 Notes may declare all the 2028 Notes to be due and payable immediately, and (ii) the Trustee and the holders of at least 25% in aggregate principal amount of the then outstanding 2032 Notes may declare all the 2032 Notes to be due and payable immediately.

     

    The foregoing is a brief description of certain terms of the Indentures and, by its nature, is incomplete. It is qualified in its entirety by the text of the Indentures. The Company is filing the Sixteenth Supplemental Indenture as Exhibit 4.1 to this Current Report on Form 8-K and the Seventeenth Supplemental Indenture as Exhibit 4.2 to this Current Report on Form 8-K, and has filed the Base Indenture with the Securities and Exchange Commission on November 23, 2009 as Exhibit 4.1 to the Company’s Current Report on Form 8-K, all of which are incorporated herein by reference.

     

     

     

     

    Item 2.03 Creation of a Direct Financial Obligation or an Obligation Under an Off-Balance Sheet Arrangement of a Registrant.

     

    The information set forth in Item 1.01 above with respect to the Indentures and the Notes is hereby incorporated by reference into this Item 2.03 insofar as it relates to the creation of a direct financial obligation.

     

    Item 8.01 Other Events.

     

    The legal opinion of Morgan, Lewis & Bockius LLP as to the validity of the Notes is attached as Exhibit 5.1 to this Current Report on Form 8-K and such opinion contains the consent of Morgan, Lewis & Bockius LLP to the filing of its opinion as an exhibit to this Current Report on Form 8-K.

     

    Forward-Looking Statements

     

    Certain of the statements contained in this Current Report on Form 8-K are “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended (the “Securities Exchange Act”). Words such as “aim,” “anticipate,” “believe,” “can,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “might,” “on track,” “opportunity,” “plan,” “possible,” “potential,” “predict,” “project,” “seek,” “should,” “strive,” “sustain,” “synergy,” “target,” “will,” “would” and similar expressions are intended to identify forward-looking statements, but the absence of these words does not mean that a statement is not forward-looking. These statements are based on management’s current expectations and are subject to uncertainty and changes in circumstances and speak only as of the date hereof. These statements are not guarantees of future performance and are based on assumptions and estimates that could prove incorrect or could cause actual results to vary materially from those indicated. A more detailed discussion of the risks and uncertainties that could cause the Company’s actual results to differ materially from those indicated is included in the “Risk Factors” and “Management’s Discussion and Analysis” sections in the Company’s Annual Report on Form 10-K for the fiscal year ended September 30, 2024 and elsewhere in that report and other reports filed by the Company pursuant to the Securities Exchange Act. The Company undertakes no obligation to publicly update or revise any forward-looking statements, except as required by the federal securities laws.

     

    Item 9.01 Financial Statements and Exhibits.

     

    Exhibit
    Number
      Description
    4.1   Sixteenth Supplemental Indenture, dated May 22, 2025, by and among Cencora, Inc., U.S. Bank Europe DAC, U.K. Branch and U.S. Bank Trust Company, National Association (including Form of 2.875% Senior Note due 2028).
    4.2   Seventeenth Supplemental Indenture, dated May 22, 2025, by and among Cencora, Inc., U.S. Bank Europe DAC, U.K. Branch and U.S. Bank Trust Company, National Association (including Form of 3.625% Senior Note due 2032).
    5.1   Opinion of Morgan, Lewis & Bockius LLP.
    23.1   Consent of Morgan, Lewis & Bockius LLP (contained in Exhibit 5.1).
    104   Cover Page Interactive Data File (formatted as inline XBRL)

     

     

     

     

    SIGNATURES

     

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

     

      Cencora, Inc.
       
    May 22, 2025 By: /s/ James F. Cleary
        Name: James F. Cleary
        Title: Executive Vice President and Chief Financial Officer

     

     

     

    Get the next $COR alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $COR

    DatePrice TargetRatingAnalyst
    12/4/2024$280.00Outperform
    Mizuho
    9/18/2024$275.00 → $245.00Buy → Neutral
    BofA Securities
    2/26/2024$261.00Outperform
    Leerink Partners
    1/3/2024$242.00Overweight
    Barclays
    12/14/2023$213.00Equal Weight
    Wells Fargo
    12/14/2021$162.00 → $170.00Buy → Neutral
    Citigroup
    11/26/2021$136.00 → $170.00Sector Perform
    RBC Capital
    11/16/2021Underweight → Equal-Weight
    Barclays
    More analyst ratings

    $COR
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Cencora Elects Lori J. Ryerkerk to Its Board of Directors

      Cencora, Inc. (NYSE:COR) today announced that its Board of Directors has elected Lori J. Ryerkerk as a new independent director, effective June 1, 2025. "Ms. Ryerkerk's experience in complex, global supply chains will further strengthen the Board's expertise as we continue supporting the company's long-term growth. Her appointment reflects the Cencora Board's ongoing commitment to leaders who can help us contribute to driving stakeholder value," said Mark Durcan, Lead Independent Director. "Lori's experience as a public company CEO, leading a global specialties chemical company with extensive operations and logistics, will bring valuable insight as we execute against our strategy and bu

      5/28/25 7:30:00 AM ET
      $COR
      Other Pharmaceuticals
      Health Care
    • Cencora Reports Fiscal 2025 Second Quarter Results

      Revenue of $75.5 billion for the Second Quarter, a 10.3 percent Increase Year-Over-Year Second Quarter GAAP Diluted EPS of $3.68 and Adjusted Diluted EPS of $4.42 Adjusted Diluted EPS Guidance Range Raised to $15.70 to $15.95 for Fiscal 2025 Cencora, Inc. (NYSE:COR) reported that in its fiscal year 2025 second quarter ended March 31, 2025, revenue increased 10.3 percent year-over-year to $75.5 billion. On the basis of U.S. generally accepted accounting principles (GAAP), diluted earnings per share (EPS) was $3.68 for the second quarter of fiscal 2025 compared to $2.09 in the prior year second quarter. Adjusted diluted EPS, which is a non-GAAP financial measure that excludes items described

      5/7/25 6:30:00 AM ET
      $COR
      Other Pharmaceuticals
      Health Care
    • Cencora Announces Date and Time for Second Quarter Fiscal 2025 Earnings Release

      Cencora, Inc. (NYSE:COR) today announced that it plans to release its results for the Second Quarter of Fiscal 2025 on Wednesday, May 7, 2025, prior to the opening of trading on the New York Stock Exchange. The Company will host a conference call to discuss the results at 8:30 a.m. ET on May 7, 2025. Participating in the conference call will be: Robert P. Mauch, President & Chief Executive Officer James F. Cleary, Executive Vice President & Chief Financial Officer The live call will be webcast via the Company's website at investor.cencora.com. Users are encouraged to log on to the webcast approximately 10 minutes in advance of the scheduled start time of the call. To access the call via

      3/28/25 7:00:00 AM ET
      $COR
      Other Pharmaceuticals
      Health Care

    $COR
    Financials

    Live finance-specific insights

    See more
    • Cencora Reports Fiscal 2025 Second Quarter Results

      Revenue of $75.5 billion for the Second Quarter, a 10.3 percent Increase Year-Over-Year Second Quarter GAAP Diluted EPS of $3.68 and Adjusted Diluted EPS of $4.42 Adjusted Diluted EPS Guidance Range Raised to $15.70 to $15.95 for Fiscal 2025 Cencora, Inc. (NYSE:COR) reported that in its fiscal year 2025 second quarter ended March 31, 2025, revenue increased 10.3 percent year-over-year to $75.5 billion. On the basis of U.S. generally accepted accounting principles (GAAP), diluted earnings per share (EPS) was $3.68 for the second quarter of fiscal 2025 compared to $2.09 in the prior year second quarter. Adjusted diluted EPS, which is a non-GAAP financial measure that excludes items described

      5/7/25 6:30:00 AM ET
      $COR
      Other Pharmaceuticals
      Health Care
    • Cencora Announces Date and Time for Second Quarter Fiscal 2025 Earnings Release

      Cencora, Inc. (NYSE:COR) today announced that it plans to release its results for the Second Quarter of Fiscal 2025 on Wednesday, May 7, 2025, prior to the opening of trading on the New York Stock Exchange. The Company will host a conference call to discuss the results at 8:30 a.m. ET on May 7, 2025. Participating in the conference call will be: Robert P. Mauch, President & Chief Executive Officer James F. Cleary, Executive Vice President & Chief Financial Officer The live call will be webcast via the Company's website at investor.cencora.com. Users are encouraged to log on to the webcast approximately 10 minutes in advance of the scheduled start time of the call. To access the call via

      3/28/25 7:00:00 AM ET
      $COR
      Other Pharmaceuticals
      Health Care
    • Walgreens Boots Alliance Early-Settles Certain Prepaid Variable Share Forward Transactions and Sells Related Shares of Cencora For Approximately $300 Million of Proceeds

      Transaction Highlights Walgreens Boots Alliance announces early settlement of certain prepaid variable share forward transactions with respect to shares of Cencora for delivery of an aggregate 6.1 million shares Concurrent with the early settlement, the Company executed a sale of the remaining 1.3 million shares of Cencora pledged under the early settled contracts. The Company receives approximately $300 million from the early settlement and the concurrent sale of shares Following today's early settlement, the Company owns approximately 12.6 million shares of Cencora pledged under the remaining prepaid variable share forward contracts, which have the potential to provide additional

      2/6/25 8:30:00 PM ET
      $COR
      $WBA
      Other Pharmaceuticals
      Health Care
      Retail-Drug Stores and Proprietary Stores
      Consumer Staples

    $COR
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Mizuho resumed coverage on Cencora with a new price target

      Mizuho resumed coverage of Cencora with a rating of Outperform and set a new price target of $280.00

      12/4/24 7:30:44 AM ET
      $COR
      Other Pharmaceuticals
      Health Care
    • Cencora downgraded by BofA Securities with a new price target

      BofA Securities downgraded Cencora from Buy to Neutral and set a new price target of $245.00 from $275.00 previously

      9/18/24 8:27:47 AM ET
      $COR
      Other Pharmaceuticals
      Health Care
    • Leerink Partners initiated coverage on Cencora with a new price target

      Leerink Partners initiated coverage of Cencora with a rating of Outperform and set a new price target of $261.00

      2/26/24 7:28:01 AM ET
      $COR
      Other Pharmaceuticals
      Health Care

    $COR
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Cencora Inc.

      SC 13G/A - Cencora, Inc. (0001140859) (Subject)

      11/14/24 1:22:34 PM ET
      $COR
      Other Pharmaceuticals
      Health Care
    • Amendment: SEC Form SC 13D/A filed by Cencora Inc.

      SC 13D/A - Cencora, Inc. (0001140859) (Subject)

      8/5/24 6:43:49 PM ET
      $COR
      Other Pharmaceuticals
      Health Care
    • SEC Form SC 13G/A filed by CoreSite Realty Corporation (Amendment)

      SC 13G/A - CoreSite Realty Corp (0001490892) (Subject)

      7/12/21 8:29:18 AM ET
      $COR
      Other Pharmaceuticals
      Health Care

    $COR
    Leadership Updates

    Live Leadership Updates

    See more

    $COR
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more

    $COR
    SEC Filings

    See more

    $COR
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Cencora Expands Enterprise Leadership Team with Two Senior Appointments

      Francois Mandeville Named Executive Vice President, Strategy and M&A Pawan Verma Appointed Executive Vice President, Chief Data and Information Officer Cencora, Inc. (NYSE:COR) today announced the appointment of Francois Mandeville as Executive Vice President, Strategy and M&A, and Pawan Verma as Executive Vice President, Chief Data and Information Officer. Both leaders will join Cencora's enterprise leadership team, bringing their extensive experience and expertise to help advance the company's pharmaceutical-centric strategy and drive growth for Cencora and its customers. "We're thrilled to welcome Francois and Pawan to Cencora's leadership team," said Bob Mauch, President and Chief Ex

      11/4/24 8:30:00 AM ET
      $COR
      Other Pharmaceuticals
      Health Care
    • Network Wireless Solutions (NWS) Appoints Michael Millegan to Board of Directors

      The communications industry veteran brings years of experience to NWS Network Wireless Solutions, LLC ("NWS"), a rapidly growing solutions and logistics provider to carriers and telecommunications contractors, announced today the appointment of Michael Millegan to its board. NWS is a portfolio company of Grain Management, LLC ("Grain"), a leading Washington, D.C.-based investment firm focused on the global communications sector. Mr. Millegan is a seasoned technology executive with several years of experience leading company strategy, including sales, marketing, supply chain operations, cell site build-out, and engineering. Currently, Mr. Millegan serves as an independent board director fo

      9/14/21 2:00:00 PM ET
      $AXS
      $COR
      $POR
      $WTT
      Property-Casualty Insurers
      Finance
      Other Pharmaceuticals
      Health Care
    • Durcan Dermot Mark bought $109,290 worth of shares (500 units at $218.58), increasing direct ownership by 2% to 21,876 units (SEC Form 4)

      4 - Cencora, Inc. (0001140859) (Issuer)

      5/29/24 4:02:27 PM ET
      $COR
      Other Pharmaceuticals
      Health Care
    • SEC Form SD filed by Cencora Inc.

      SD - Cencora, Inc. (0001140859) (Filer)

      5/30/25 4:11:02 PM ET
      $COR
      Other Pharmaceuticals
      Health Care
    • Cencora Inc. filed SEC Form 8-K: Leadership Update, Regulation FD Disclosure, Financial Statements and Exhibits

      8-K - Cencora, Inc. (0001140859) (Filer)

      5/28/25 5:02:29 PM ET
      $COR
      Other Pharmaceuticals
      Health Care
    • SEC Form CERT filed by Cencora Inc.

      CERT - Cencora, Inc. (0001140859) (Filer)

      5/27/25 10:11:59 AM ET
      $COR
      Other Pharmaceuticals
      Health Care
    • President & CEO Mauch Robert P. exercised 3,225 shares at a strike of $86.09 and sold $1,448,116 worth of shares (4,969 units at $291.43), decreasing direct ownership by 4% to 45,838 units (SEC Form 4)

      4 - Cencora, Inc. (0001140859) (Issuer)

      5/21/25 4:04:03 PM ET
      $COR
      Other Pharmaceuticals
      Health Care
    • Executive Chairman Collis Steven H sold $4,283,600 worth of shares (14,578 units at $293.84) and exercised 12,578 shares at a strike of $86.09, decreasing direct ownership by 0.63% to 313,913 units (SEC Form 4)

      4 - Cencora, Inc. (0001140859) (Issuer)

      5/21/25 4:00:46 PM ET
      $COR
      Other Pharmaceuticals
      Health Care
    • Director Greenberg Lon R sold $837,150 worth of shares (3,000 units at $279.05), decreasing direct ownership by 14% to 17,851 units (SEC Form 4)

      4 - Cencora, Inc. (0001140859) (Issuer)

      5/16/25 4:23:09 PM ET
      $COR
      Other Pharmaceuticals
      Health Care